Table 1. Associations between CD68, CD163 and AXL proteins expression and clinicopathological features in triple-negative breast cancer.
| Clinicopathological characteristics |
CD68 |
CD163 |
AXL |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | High expression (%) | Low expression (%) | P valuea | N | High expression (%) | Low expression (%) | P valuea | N | High expression (%) | Low expression (%) | P valuea | |
|
Age at diagnosis | ||||||||||||
| <50 | 102 | 39 (38.2) | 63 (61.8) | 2.57E−01 | 102 | 44 (43.1) | 58 (56.9) | 8.88E−01 | 102 | 37 (36.3) | 65 (63.7) | 6.66E−01 |
| ⩾50 | 101 | 47 (46.5) | 54 (53.5) | 101 | 45 (44.6) | 56 (55.4) | 101 | 40 (39.6) | 61 (60.4) | |||
|
Lymph node status | ||||||||||||
| Negative | 96 | 35 (36.5) | 61 (63.5) | 1.19E−01 | 96 | 37 (38.5) | 59 (58.3) | 1.59E−01 | 96 | 29 (30.2) | 67 (69.8) | 4.20E−02 |
| Positive | 107 | 51 (47.7) | 56 (52.3) | 107 | 52 (48.6) | 55 (51.4) | 107 | 48 (44.9) | 59(55.1) | |||
|
Histological grade | ||||||||||||
| G1–2 | 48 | 21 (43.7) | 27 (56.3) | 8.68E−01 | 48 | 26 (54.2) | 22 (45.8) | 1.34E−01 | 48 | 21 (43.7) | 27 (56.3) | 3.95E−01 |
| G3 | 155 | 65 (41.9) | 90 (58.1) | 155 | 63 (40.6) | 92 (59.4) | 155 | 56 (36.1) | 99 (63.9) | |||
|
TNM staging | ||||||||||||
| I–II | 136 | 55 (40.4) | 81 (59.6) | 4.53E−01 | 136 | 58 (42.7) | 78 (57.3) | 6.54E−01 | 136 | 50 (36.8) | 86 (63.2) | 6.47E−01 |
| III | 67 | 31 (46.3) | 36 (53.7) | 67 | 31 (46.3) | 36 (53.7) | 67 | 27 (40.3) | 40 (59.7) | |||
|
Tumor size (mm) | ||||||||||||
| ⩽20 | 105 | 42 (40.0) | 63 (60.0) | 4.78E−01 | 105 | 47 (44.8) | 58 (55.2) | 8.88E−01 | 105 | 39 (37.1) | 66 (62.9) | 7.74E−01 |
| >20 | 97 | 44 (45.4) | 53 (54.6) | 97 | 42 (43.3) | 55 (56.7) | 97 | 38 (39.2) | 59 (60.8) | |||
|
Lymphovascular invasion | ||||||||||||
| Absent | 65 | 29 (44.6) | 36 (55.4) | 4.06E−01 | 65 | 29 (44.6) | 36 (55.4) | 8.39E−01 | 65 | 24 (36.9) | 41 (63.1) | 8.35E−01 |
| Present | 38 | 13 (34.2) | 25 (65.8) | 38 | 16 (42.1) | 22 (57.9) | 38 | 15 (39.5) | 23 (60.5) | |||
|
Recurrence | ||||||||||||
| Yes | 47 | 26 (55.3) | 21 (44.7) | 4.50E−02 | 47 | 28 (59.6) | 19 (40.4) | 1.80E−02 | 47 | 31 (66.0) | 16 (34.0) | <1.00E−04 |
| No | 156 | 60 (38.5) | 96 (61.5) | 156 | 61 (39.1) | 95 (60.9) | 156 | 46 (29.5) | 110 (70.5) | |||
|
First site of distant metastasis | ||||||||||||
| Bone | 8 | 2 (25.0) | 6 (75.0) | 1.01E−01 | 8 | 4 (50.0) | 4 (50.0) | 6.95E−01 | 8 | 3 (37.5) | 5 (62.5) | 3.60E−02 |
| Visceral | 25 | 16 (64.0) | 9 (36.0) | 25 | 15 (60.0) | 10 (40.0) | 25 | 20 (80.0) | 5 (20.0) | |||
a
Significant P values (Fisher’s exact test) are given in bold.